×
LIOM is developing a highly promising solution that combines hardware and software with a high level of technological innovation at the intersection of photonics, MedTech, machine learning, and medicine.
The Jury particularly appreciated the company’s core innovation and clear USP: transforming blood chemistry into a continuous, non-invasive wearable signal with an unmatched level of precision, without the need for needles. The initial product focuses on glucose monitoring, with the underlying technology offering significant potential for expansion to additional biomarkers.
The Jury also valued LIOM’s strong IP portfolio, the outstanding scientific and entrepreneurial expertise of the team, which includes successful serial entrepreneurs, as well as the impressive traction the company has achieved with investors.